Switch theme
Sign up to access all valuation multiples
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
2008
279
LTM Revenue $146M
Last FY EBITDA -$38.6M
$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Karyopharm Therapeutics has a last 12-month revenue (LTM) of $146M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Karyopharm Therapeutics achieved revenue of $145M and an EBITDA of -$38.6M.
Karyopharm Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Karyopharm Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $146M | XXX | $145M | XXX | XXX | XXX |
| Gross Profit | $140M | XXX | $139M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$38.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBIT | -$114M | XXX | -$119M | XXX | XXX | XXX |
| EBIT Margin | -79% | XXX | -82% | XXX | XXX | XXX |
| Net Profit | -$99.1M | XXX | -$76.4M | XXX | XXX | XXX |
| Net Margin | -68% | XXX | -53% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $125M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Karyopharm Therapeutics's stock price is $4.
Karyopharm Therapeutics has current market cap of $36.3M, and EV of $153M.
See Karyopharm Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $36.3M | XXX | XXX | XXX | XXX | $-13.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Karyopharm Therapeutics has market cap of $36.3M and EV of $153M.
Karyopharm Therapeutics's trades at 1.1x EV/Revenue multiple, and -4.0x EV/EBITDA.
Equity research analysts estimate Karyopharm Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Karyopharm Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for Karyopharm Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.3M | XXX | $36.3M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.0x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKaryopharm Therapeutics's last 12 month revenue growth is 5%
Karyopharm Therapeutics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.9M for the same period.
Karyopharm Therapeutics's rule of 40 is -76% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Karyopharm Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Karyopharm Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -76% | XXX | -21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 178% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Karyopharm Therapeutics acquired XXX companies to date.
Last acquisition by Karyopharm Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Karyopharm Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Karyopharm Therapeutics founded? | Karyopharm Therapeutics was founded in 2008. |
| Where is Karyopharm Therapeutics headquartered? | Karyopharm Therapeutics is headquartered in United States of America. |
| How many employees does Karyopharm Therapeutics have? | As of today, Karyopharm Therapeutics has 279 employees. |
| Who is the CEO of Karyopharm Therapeutics? | Karyopharm Therapeutics's CEO is Mr. Richard Paulson, M.B.A.. |
| Is Karyopharm Therapeutics publicy listed? | Yes, Karyopharm Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Karyopharm Therapeutics? | Karyopharm Therapeutics trades under KPTI ticker. |
| When did Karyopharm Therapeutics go public? | Karyopharm Therapeutics went public in 2013. |
| Who are competitors of Karyopharm Therapeutics? | Similar companies to Karyopharm Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Karyopharm Therapeutics? | Karyopharm Therapeutics's current market cap is $36.3M |
| What is the current revenue of Karyopharm Therapeutics? | Karyopharm Therapeutics's last 12 months revenue is $146M. |
| What is the current revenue growth of Karyopharm Therapeutics? | Karyopharm Therapeutics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Karyopharm Therapeutics? | Current revenue multiple of Karyopharm Therapeutics is 1.1x. |
| Is Karyopharm Therapeutics profitable? | Yes, Karyopharm Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
